Skip to main content

Avantor, Inc. (AVTR) Stock Analysis

Recovery setup

SellModerate Confidence

Healthcare · Medical Instruments & Supplies

Sell if holding. Engine safety override at $8.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.

Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company... Read more

$8.20+12.0% A.UpsideScore 5.2/10#15 of 25 Medical Instruments & Supplies
Stop $7.64Target $9.20(analyst − 13%)A.R:R 1.2:1
Analyst target$10.58+29.0%13 analysts
$9.20our TP
$8.20price
$10.58mean
$19

Sell if holding. Engine safety override at $8.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Score 5.2/10, moderate confidence.

Passes 4/7 gates (clean insider activity, no SEC red flags, earnings proximity no date, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA). Suitability: moderate.

Thesis

Rewards
No bull case signals
Risks
Quality below floor (3.4 < 4.0)

Key Metrics

P/E (TTM)
P/E (Fwd)9.2
Mkt Cap$5.4B
EV/EBITDA9.5
Profit Mgn-8.4%
ROE-9.4%
Rev Growth0.0%
Beta
DividendNone
Rating analysts25

Quality Signals

Piotroski F8/9

Options Flow

P/C0.41bullish
IV90%elevated
Max Pain$30+265.9% vs spot

Concentration Risks(10-K Item 1A)

  • MEDIUMSuppliersole-sourced raw materials
    10-K Item 1A: 'many of which are sole-sourced due to market or customer demands'

Material Events(8-K, last 90d)

  • 2026-04-01Item 5.02HIGH
    CFO R. Brent Jones resigned to join a company outside the life sciences industry; 90-day notice required. Steven Eck (SVP, Chief Accounting Officer) named interim CFO pending permanent search. No permanent successor named.
    SEC filing →
  • 2026-04-23Item 5.02MEDIUM
    Benoit Gourdier (EVP, Bioscience and Medtech Products) transitioning to a supporting role, expected to depart by December 31, 2026. Ludovic Brellier hired as new EVP effective May 1, 2026. Clean handoff with named successor.
    SEC filing →

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

5 floor-breakers

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Erm
1.0
News Activity
8.0
Estimates down -15.3% (30d)Earnings concerns: 1B/3M

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

52w Position
0.0
Bollinger
3.9
Support Resistance
4.6

Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static

Roe
0.0
Net Margin
0.0
Roa
1.8
Gross Margin
2.4
Operating Margin
2.5
Moat
5.0
Current Ratio
6.3
Piotroski F
8.9
No competitive moatStrong Piotroski F-Score: 8/9

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Volume
0.0
Obv
1.0
Rsi
4.5
Ma Position
6.0
Macd
6.1
Volume distribution (falling OBV)Below 200-MA, MA slope -6.8%/30d — confirmed downtrend

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Quality Rank
1.5
Growth Rank
5.0
Value Rank
8.8
GatesMomentum 3.5<4.5A.R:R 1.2 < 1.5@spotDeath cross (50MA < 200MA)Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY NO DATESEMI CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
57 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $7.46Resistance $8.85

Price Targets

$8
$9
A.Upside+12.2%
A.R:R1.2:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (3.4 < 4.0)
! Momentum score 3.5/10 — below 4.5 minimum
! Reward/Risk 1.2:1 at current price — below 1.5:1 minimum

Earnings

B
M
M
M
1/4 beats
Next Earnings2026-04-29 (nulld)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is AVTR stock a buy right now?

Sell if holding. Engine safety override at $8.20: Quality below floor (3.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 57. Prior stop was $7.64. Score 5.2/10, moderate confidence.

What is the AVTR stock price target?

Take-profit target: $9.20 (+12.0% upside). Prior stop was $7.64. Stop-loss: $7.64.

What are the risks of investing in AVTR?

Quality below floor (3.4 < 4.0).

Is AVTR overvalued or undervalued?

Avantor, Inc. trades at a P/E of N/A (forward 9.2). TrendMatrix value score: 8.3/10. Verdict: Sell.

What do analysts say about AVTR?

25 analysts cover AVTR with a consensus score of 2.8/5. Average price target: $11.

What does Avantor, Inc. do?Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced...

Avantor is a global provider of mission-critical products and services to biopharma, education/government, and advanced technology markets through two segments: Laboratory Solutions (VWR distribution channel) and Bioscience Production (specialty manufacturing). The company serves more than 300,000 customer locations in approximately 180 countries with more than 85% of net sales from recurring offerings.

Related stocks: WST (West Pharmaceutical Services, I) · MMSI (Merit Medical Systems, Inc.) · STVN (Stevanato Group S.p.A.) · RMD (ResMed Inc.) · ATRC (AtriCure, Inc.)